Article Text

Download PDFPDF

  1. Beatrice Greco1,
  2. Thomas Spangenberg1,
  3. Elly Kourany-Lefoll1,
  4. Claude Oeuvray1,
  5. Jim Mulry2,
  6. Kamala Tyagarajan3,
  7. Bettina Magsaam4
  1. 1Merck KGaA (Ares Trading S.A.), Switzerland
  2. 2Merck KGaA (EMD Serono Inc.), Switzerland
  3. 3Merck KGaA (EMD Millipore Corporation), United States of America
  4. 4Merck KGaA, Darmstadt, Germany


Background Integrated health care approaches are the most effective ways to tackle infectious diseases such as malaria. Within its Global Health activities focusing on health issues of vulnerable populations within developing environments, Merck has launched a program named ‘One Merck for Malaria’ integrating development of new antimalarials with new sensitive diagnostic approaches together with improving access to personal protection.

Methods The first pillar of the program is based on drug discovery and development of new antimalarials. The second pillar focuses on development of diagnostics addressing the need for highly sensitive methods to identify low parasitaemia levels. The third pillar is to improve access to personal protection against malaria vectors.

Results Merck is carrying out screens and early drug discovery with its partners, Medicines for Malaria Venture (MMV, Switzerland) and H3D (University of Cape Town, South Africa), to identify new compounds to address current gaps in existing antimalarials. Furthermore Merck is conducting regulatory preclinical activities to reach clinical phase 1 of a compound originated by Dundee University (UK). Based on its excellent efficacy and pharmaceutical profile shown in pre-clinical models, it is intended to be developed as a long-lasting single oral combination treatment for uncomplicated P. falciparum and P. vivax. Other research activities focusing on target identification are conducted. The portable MUSE® cytofluorometer system is launched in African countries to measure the number and % of CD4 cells. An additional set of P. falciparum and P. vivax detection kits are in development to detect type and parasitaemia levels in low blood quantities. Merck IR3535 is a widely used insect repellent being retested to assess the degree of its efficacy against various Anopheles carrying P. falciparum in Africa.

Conclusions Besides the drug and technology developments, the program covers also aspects of e-health, education, and local capacity building to complement the integrated approach being applied at Merck.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.